According to filings with the U.S. Securities and Exchange Commission, Myoptechs is raising up to $2,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Paul Grimm played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Myoptechs
Myoptechs is an ophthalmic medical device company developing a novel soft contact lens specifically designed to slow the progression of myopia while providing exceptionally clear vision. Often called nearsightedness, myopia is a chronic, progressive eye disease that starts early in life and is characterized by worsening distance vision and excessive eye elongation. Any degree of myopia increases the risk of sight-threatening complications, including cataracts, glaucoma, retinal detachment, and myopic macular degeneration, with certain complications leading to blindness in adulthood. The mission of Myoptechs is to help reduce the short- and long-term vision implications of the disease.

To learn more about Myoptechs, visit http://www.myoptechs.com/
Myoptechs Linkedin Page: https://www.linkedin.com/company/myoptechs/

Contact:
Paul Grimm, Chief Executive Officer
614-804-8193

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.